中文

金城医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥0.75B+3.9%
Gross profit¥0.26B
Operating income¥0.08B
Net income¥0.06B+62.6%
Gross margin34.6%Net margin 7.9%
Revenue Q/Q-6.8%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.49B65.4%
R&D¥0.04B5.1%
SG&A¥0.13B17.5%
Tax & other¥0.02B2.4%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

开尔新材方直科技上海新阳ST美晨冠昊生物东宝生物飞力达瑞丰光电佳云科技瑞丰高材迪安诊断ST天玑

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies